Feldstein’s participation reflects the growing interest of major pharmaceutical companies in aging-related biology as a source of therapeutic opportunities. Rather than treating aging as a single disease, geroscience investigates the interconnected biological processes that increase vulnerability to multiple age-associated conditions. These processes can include cellular senescence, chronic inflammation, mitochondrial dysfunction, loss of proteostasis, epigenetic alterations, impaired tissue repair and declining immune function. Researchers increasingly hope that interventions aimed at these mechanisms could delay or reduce the risk of several diseases simultaneously, extending the period of life spent in good health rather than merely increasing total lifespan.

That scientific shift has created a new class of drug-development questions. Researchers must determine which biological features of aging are causally responsible for disease, which can be safely modified, and how those changes can be measured in humans. Potential indicators include molecular signatures in blood, DNA-methylation patterns, inflammatory markers, imaging measurements, physical-performance data and composite assessments of biological age. Yet a biomarker is not automatically a therapeutic target, and a change in biological age does not necessarily demonstrate that a treatment will prevent disease. Establishing clinically meaningful endpoints remains one of the central challenges facing longevity medicine.

“The biology of aging has become one of the most promising frontiers in biomedical science,” said Vadim Gladyshev, executive chair of ARDD and professor of medicine at Harvard University. He said the field must combine a deeper understanding of aging with the development of interventions that improve healthspan, the period of life spent in relatively good health. According to Gladyshev, progress will require collaboration across disciplines and sectors, because discoveries in molecular biology must ultimately be tested through rigorous translational and clinical research.

ARDD 2026 is being presented as a meeting point between those stages of discovery. Academic laboratories are investigating the molecular architecture of aging, while biotechnology companies are developing programs designed to influence senescent cells, immune aging, metabolic regulation, tissue regeneration and other age-related pathways. Pharmaceutical companies bring experience in medicinal chemistry, toxicology, clinical-trial design, manufacturing and regulatory strategy. Investors, meanwhile, are evaluating whether emerging longevity technologies can produce reproducible clinical benefits at a scale compatible with modern health-care systems.

The conference will include leaders from ten of the world’s major pharmaceutical companies and a broad network of sponsors from the pharmaceutical, biotechnology, nutrition, diagnostics, finance and consumer-health sectors. Insilico Medicine and Eli Lilly are identified as Tier 1 sponsors, with the McKinsey Health Institute serving as the sole knowledge partner. Additional sponsors include AbbVie, AniVC, AstraZeneca, BioAge Labs, Biocytogen, Cambrian Bio, Cyclarity Therapeutics, Dior, GlycanAge, Gordian Biotechnology, Human Longevity, the Institute for Healthier Living Abu Dhabi, LongeVC, Maxwell Biosciences, Nestlé, Tally Health and TruDiagnostic. Synaro Capital, The Cat Health Company and PranaGen Bioscience are supporting the meeting as Tier 4 sponsors, while Estée Lauder, Morgan Stanley, the Intrinsic Capacity Frailty & Sarcopenia Research Conference for Healthy Longevity and QuadraScope are listed as Tier 5 sponsors.

The commercial scale of that ecosystem illustrates how quickly longevity research has entered the mainstream of biomedical innovation. However, the expansion of investment also increases pressure on researchers and companies to distinguish scientifically validated approaches from premature claims. Aging is a complex, multiscale process, and interventions that appear beneficial in cells or laboratory animals may fail in humans because of differences in metabolism, immune response, disease history or treatment duration. For this reason, the most consequential discussions at meetings such as ARDD are likely to center on reproducibility, patient selection, safety, trial endpoints and the evidence required to show that a therapy changes clinically important outcomes.

Morten Scheibye-Knudsen, co-chair of ARDD and associate professor at the University of Copenhagen, said the meeting’s move to Boston marks a new stage for the conference. Boston and the surrounding region form one of the world’s most concentrated biomedical research and drug-development ecosystems, linking universities, hospitals, biotechnology companies and pharmaceutical organizations. Scheibye-Knudsen described ARDD 2026 as increasingly focused on translating discoveries into medicines, a transition that requires researchers to connect fundamental mechanisms of aging with practical therapeutic programs.

Alex Zhavoronkov, Ph.D., co-chair of ARDD and chief executive officer of Insilico Medicine, said the meeting has served for more than a decade as a platform for dialogue among academia, pharmaceutical companies, startups and investors. Insilico Medicine is officially organizing the 2026 event. The company’s role places the conference within a broader industry movement that uses artificial intelligence, large biological datasets and computational drug-discovery methods to identify targets and design candidate molecules. Such technologies may accelerate early research, but their value will ultimately depend on experimental validation and evidence from human studies.

ARDD is now in its 13th year and is described by its organizers as the world’s largest meeting dedicated to aging and longevity biotechnology. The 2026 program is intended to examine how advances in the biology of aging can be converted into research-and-development strategies and therapeutic candidates. The Nordic Aging Society, a nonprofit scientific organization dedicated to aging research and collaboration across the Nordic region and beyond, is supporting the meeting. With the field approaching a decisive phase—where molecular insights must be matched by clinical evidence—the Boston gathering will offer a high-profile test of whether longevity science can fulfill its promise of producing safer, more effective interventions for age-related disease and functional decline.

Subject of Research: Aging biology, geroscience, longevity biotechnology, drug discovery and the translation of aging research into clinical therapies.

Article Title: Pfizer Executive Ariel Feldstein to Speak at ARDD 2026 as Longevity Science Enters a New Drug-Development Era

News Publication Date: Aug. 7, 2026

Web References: https://agingpharma.org; https://mediasvc.eurekalert.org/Api/v1/Multimedia/582b0698-c395-46ef-a16b-f659f75c72f4/Rendition/low-res/Content/Public

References: ARDD 2026 announcement provided by Insilico Medicine and the ARDD organizing committee; statements attributed to Vadim Gladyshev, Morten Scheibye-Knudsen and Alex Zhavoronkov.

Image Credits: ARDD 2026

Keywords: Aging research, longevity science, geroscience, drug discovery, healthspan, biological aging, biotechnology, pharmaceutical research, clinical translation, ARDD 2026, Ariel Feldstein, Pfizer

Gerophysics represents a promising interdisciplinary field that borrows heavily from theoretical physics to address the complexities of biological aging. Historically, the application of physics has revolutionized numerous industries—from finance to artificial intelligence—reshaping our understanding of both the material world and life itself. Now, researchers are pivoting to a less conventional application of these methodologies, targeting the fundamental mechanisms that drive aging. By leveraging theoretical constructs such as statistical mechanics and complex systems theory, there lies a tantalizing potential to decode the biological enigma of aging.

The conference will be a melting pot for scholars and researchers hailing from diverse scientific backgrounds, all uniting under a common purpose. Participants will engage in discussions not only about the physics of aging but also about the biological systems involved. The synergy created by this collaborative atmosphere could lead to revolutionary breakthroughs that reshape contemporary understandings of longevity. In this light, gerophysics is positioned as a venue for intellectual exchanges that stoke creativity and innovation—a true scientific convergence.

One cornerstone of the conference is the development of a shared scientific language and toolkit for conducting aging research. Researchers often work within narrow disciplines, employing terminology and methodologies that can be at odds with those of their peers. Establishing a standardized lexicon can facilitate collaboration, making it easier for scientists from different fields to communicate effectively and work together to address common objectives. This shared language may also expedite the process of innovation, as new ideas can spread more seamlessly across disciplines.

In addition to linguistic cohesion, the conference opens doors for exploration into novel experimental frameworks. Traditional approaches to studying aging have largely focused on biological pathways and molecular mechanisms. However, viewing these processes through the lens of physics allows for the incorporation of dynamical modeling and statistical methods, which could yield fresh insights into the aging process. For example, understanding aging as a complex system influenced by various factors could shift the focus from mere characterization of cellular pathways to a broader investigation that includes environmental and lifestyle variables.

Furthermore, fostering collaborations at the conference could have far-reaching implications for extending healthy lifespans. Aging research stands at a crossroads, with many potential avenues to explore. The complexity of biological aging necessitates an integrated approach, one that breaks free from siloed thinking. By facilitating connections among diverse stakeholders, ranging from physicists and biologists to clinical researchers and public health experts, the conference aims to catalyze multi-disciplinary projects that could expedite the translation of scientific discoveries into practical applications.

What makes gerophysics particularly appealing is its foundation in collaboration. By inviting scientists and thought leaders from various specialties, the conference aims to serve as a cross-pollination ground where ideas can flourish unbounded by traditional disciplinary constraints. When physicists, biologists, and gerontologists come together, they bring unique perspectives that can enrich the dialogue surrounding aging and healthspan. The value of this collaboration cannot be understated; collectivizing expertise could lead to fresh methodologies and innovative solutions to some of the most pressing challenges in aging research.

In the global landscape where aging-related diseases like Alzheimer’s and various forms of cancer are on the rise, addressing the factors contributing to biological aging has never been more urgent. The intersection of gerophysics and aging biology could illuminate the pathways involved in the onset and progression of these diseases. The holistic approach proposed at the conference seeks not just to extend lifespans but to enhance the quality of life as we age, laying the groundwork for a healthier population in the years to come.

As we await the advent of this groundbreaking conference, interest is surging within the scientific community. Being recognized as a media partner, Aging (Aging-US) is poised to amplify the significance of the event and its outcomes. The journal’s commitment to disseminating insights from the conference reflects a deeper purpose: to ensure that findings reach a broad audience, fostering advancements in the understanding of aging worldwide.

To stay engaged with the themes of the conference, scientists and enthusiasts can follow updates via social media platforms like LinkedIn and X (formerly Twitter). These channels will serve as conduits, enabling the broader community to remain connected with ongoing discussions, emerging research, and future initiatives emanating from the convergence of physics and gerontology.

As the concept of gerophysics continues to unfold, its implications extend beyond academia. It holds the potential to inform public health policies and educational initiatives aimed at promoting healthy aging. The ideas and collaborations birthed at the Global Conference on Gerophysics may well lead to a new standard of care and understanding regarding age-related diseases—a significant leap towards a future where aging is not merely endured, but embraced as a natural part of the human experience.

With such promising avenues for exploration and collaboration on the horizon, the Global Conference on Gerophysics positions itself as a beacon of hope in the quest for longevity. As experts gather to chart new territories in the intersection of physics and biology, the collective efforts could illuminate pathways to healthier, longer lives, paving the way for groundbreaking advancements in the study of aging.

This vase of potential spells excitement for researchers, institutions, and ultimately, for society at large. The dedication to seeking interdisciplinary solutions in the often-complex field of aging could redefine not only how we perceive the biological aging process but also how we address the profound challenges that accompany it.

Subject of Research: Gerophysics – The Intersection of Physics and Aging Biology
Article Title: The Convergence of Physics and Aging: A New Era in Gerophysics
News Publication Date: January 21, 2025
Web References: Aging (Aging-US), Global Conference on Gerophysics
References: N/A
Image Credits: National University of Singapore (NUS) Yong Loo Lin School of Medicine

Keywords

Aging, Gerophysics, Longevity, Research, Conference, Physics, Biology, Collaboration, Healthspan, Lifespan, Interdisciplinary Science, Aging Research